This Article Full Text Full Text (PDF) Other Versions of this Article: CVI.00284-07v1 15/2/267    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Currier, J. R. Articles by Cox, J. H. Search for Related Content PubMed PubMed Citation Articles by Currier, J. R. Articles by Cox, J. H.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, February 2008, p. 267-276, Vol. 15, No. 2
1071-412X/08/$08.00+0     doi:10.1128/CVI.00284-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Peptide Impurities in Commercial Synthetic Peptides and Their Implications for Vaccine Trial Assessment

U.S. Military HIV Research Program, Rockville, Maryland,¹ JPT Peptide Technologies, Berlin, Germany,² National Institute for Communicable Diseases, Sandringham, Johannesburg, South Africa,³ Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand,⁴ Mbeya Medical Research Programme, Mbeya, Tanzania,⁵ Department of Infectious Diseases and Tropical Medicine, University of Munich, Munich, Germany⁶

Received 11 July 2007/ Returned for modification 9 October 2007/ Accepted 21 November 2007

The advent of T-cell assay methodologies that are amenable to high throughput coupled with the availability of large libraries of overlapping peptides have revolutionized the fields of vaccine efficacy testing and cellular immune response assessment. Since T-cell assay performance is critically dependent upon the quality and specificity of the stimulating peptides, assurance of high-quality and reliable input peptides is an important aspect of assay validation. Herein, we demonstrate that individual peptides from large human immunodeficiency virus (HIV)-based peptide library sets obtained directly from two independent custom peptide suppliers contained contaminating peptides capable of giving false-positive results, which were consistent with nominal antigen-specific CD8⁺ T-cell responses. In-depth investigation of the cellular response in terms of responding CD8⁺ T-cell frequency and human leukocyte antigen (HLA) restriction led to the conclusion that one set of HIV type 1 (HIV-1)-derived peptides was contaminated with a peptide from human cytomegalovirus (HCMV), which is commonly used in cellular immunology research applications. Analytical characterization of the original stock of the suspect HIV-1 peptide confirmed the presence of 1% by weight of the HCMV peptide. These observations have critical implications for quality assurance (QA) and quality control (QC) of peptides used in clinical trials where cellular immune-based assays are important end-point determinants. We propose a simple schema of biological QA/QC protocols to augment the standard biochemical QA/QC analyses as a means to circumvent this and other problems that can affect cellular immune-based assay outcome and interpretation.

Published ahead of print on 12 December 2007.